China Approves J and J Nipocalimab for Muscle Disorder
The National Medical Products Administration approved the drug for patients aged 12 and older with generalized myasthenia gravis. Acquired through the Momenta buyout, the treatment is expected to drive growth as it enters the Chinese market alongside competitors.
Xurve View
Insights:
Xurve View
Johnson & Johnson secured approval from the National Medical Products Administration in China for its muscle-disorder treatment, nipocalimab. The drug, acquired via a $6.5 billion buyout of Momenta in 2020, targets generalized myasthenia gravis in patients 12 and older. J&J expects the treatment to generate blockbuster revenue as it expands into a market already occupied by three major competitors.
